NovoCure (NASDAQ:NVCR) Downgraded to Strong Sell Rating by Zacks Research

Posted by Brenda Bartman on Jul 16th, 2026

Zacks Research cut shares of NovoCure (NASDAQ:NVCR – Free Report) from a hold rating to a strong sell rating in a research report sent to investors on Tuesday,Zacks.com reports.

A number of other research analysts have also weighed in on NVCR. Evercore reissued an “outperform” rating on shares of NovoCure in a research note on Friday, May 1st. Weiss Ratings upgraded NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Wedbush reiterated a “neutral” rating and set a $18.00 target price on shares of NovoCure in a research report on Thursday, April 16th. HC Wainwright reissued a “buy” rating and issued a $46.00 price target (down from $48.00) on shares of NovoCure in a research note on Thursday, June 18th. Finally, JPMorgan Chase & Co. assumed coverage on NovoCure in a report on Monday. They issued a “neutral” rating and a $17.00 price target for the company. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, NovoCure presently has an average rating of “Hold” and an average target price of $23.60.

Read Our Latest Stock Report on NVCR

NovoCure Stock Performance

Shares of NASDAQ NVCR opened at $16.03 on Tuesday. The company has a market cap of $1.86 billion, a PE ratio of -10.48 and a beta of 0.94. NovoCure has a 12 month low of $9.82 and a 12 month high of $18.92. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.90 and a quick ratio of 2.70. The company has a 50-day simple moving average of $16.79 and a 200-day simple moving average of $13.97.

NovoCure (NASDAQ:NVCR – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). NovoCure had a negative net margin of 25.66% and a negative return on equity of 50.82%. The firm had revenue of $174.06 million for the quarter, compared to analysts’ expectations of $167.77 million. During the same period in the previous year, the company posted ($0.31) EPS. The business’s quarterly revenue was up 12.3% on a year-over-year basis. On average, equities analysts anticipate that NovoCure will post -1.51 earnings per share for the current year.

Insider Buying and Selling at NovoCure

In related news, Director Jeryl L. Hilleman sold 2,945 shares of NovoCure stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the transaction, the director owned 13,861 shares in the company, valued at approximately $218,587.97. This trade represents a 17.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director W Anthony Vernon sold 2,945 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total value of $46,442.65. Following the sale, the director directly owned 197,657 shares of the company’s stock, valued at approximately $3,117,050.89. This trade represents a 1.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 51,943 shares of company stock worth $893,171. 5.52% of the stock is currently owned by company insiders.

Institutional Trading of NovoCure

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in NovoCure by 4.8% in the fourth quarter. Vanguard Group Inc. now owns 10,958,209 shares of the medical equipment provider’s stock valued at $141,690,000 after buying an additional 502,368 shares during the period. Soleus Capital Management L.P. lifted its position in NovoCure by 25.0% during the second quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock valued at $122,897,000 after buying an additional 1,382,888 shares in the last quarter. Morgan Stanley grew its stake in NovoCure by 453.4% during the fourth quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider’s stock worth $65,554,000 after buying an additional 4,153,741 shares during the period. Quantinno Capital Management LP grew its stake in NovoCure by 23.7% during the first quarter. Quantinno Capital Management LP now owns 2,487,376 shares of the medical equipment provider’s stock worth $27,112,000 after buying an additional 477,128 shares during the period. Finally, Balyasny Asset Management L.P. increased its position in shares of NovoCure by 38.8% in the second quarter. Balyasny Asset Management L.P. now owns 2,270,076 shares of the medical equipment provider’s stock worth $40,407,000 after acquiring an additional 634,925 shares in the last quarter. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure Company Profile

(Get Free Report)

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.